4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke

Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke

Study Description
Brief Summary:
The goal of this study is to determine the efficacy of electromechanical exoskeleton-assisted gait training on rehabilitation functional outcomes in patients with stroke undergoing therapy in an in-patient rehabilitation facility.

Condition or disease Intervention/treatment Phase
Stroke Weakness of Extremities as Sequela of Stroke Device: Indego Exoskeleton Other: Standard Rehabilitation Not Applicable

Detailed Description:

Abstract

Objective: The goal of this study is to determine the efficacy of electromechanical exoskeleton-assisted gait training on rehabilitation functional outcomes in patients with stroke undergoing therapy in an in-patient rehabilitation facility.

Background:

Method: The investigators will study 50 patients with stroke consecutively admitted to a designated stroke rehabilitation unit in the Oklahoma City VA Medical Center. All patients will receive their daily 3-hours conventional therapy, plus an hour of either exoskeleton or over-ground gait training 3 times per week for 60 minutes. Patients were assigned to either the experimental (exoskeleton) or the control (over-ground) groups by computer-generated randomization. This is an open-label pragmatic trial, where neither the patients nor the clinicians could be masked to the intervention. Institution review board (IRB) approval will be obtained for the protocol. The demographic data to be collected includes: age, gender, race/ethnicity, stroke onset to admission, stroke types (ischemic/hemorrhagic), and stroke severity (on the National Institute of Health Stroke Severity [NIHSS] scale. Admission and discharge total Functional Independence Measure (FIM), spasticity and depression scores, ambulation velocity over 2-minutes (2-MWT) in feet/minute, and discharge disposition. The intervention is Indego® exoskeleton. The primary outcome measures were: changes in the FIM, depression and spasticity scores. The secondary outcome measure was discharge disposition. Continuous variables were analyzed using Students t-test, ordinal variables were analyzed using Mann-Whitney, and the nominal variables were analyzed using Chi-square analyses.

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Open label pragmatic study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke
Actual Study Start Date : March 1, 2020
Estimated Primary Completion Date : September 1, 2024
Estimated Study Completion Date : September 1, 2025
Arms and Interventions
Arm Intervention/treatment
Experimental: Exo-group
Standard rehabilitation plus use of Exoskeleton
Device: Indego Exoskeleton
Powered generated orthosis

Other: Standard Rehabilitation
Standard Rehabilitation

Placebo Comparator: Control-Group
Standard rehabilitation
Other: Standard Rehabilitation
Standard Rehabilitation

Outcome Measures
Primary Outcome Measures :
  1. The Functional Independence Measure (FIM™) [ Time Frame: Baseline (Day 1) and at 4-weeks to measure change ]
    It measure the degree of disability as well as the progress patients make throughout their medical rehabilitation programs. FIM Scale score varies from minimum of 18 to maximum of 126. Higher score better the outcome.

  2. The two minute walk test (2-MWT) [ Time Frame: Baseline (Day 1) and at 4-weeks to measure change ]
    It assess the walking distance over two minutes while moving at a comfortable speed. using any ambulation aids (such as cane, walkers, and rollators) used in everyday life. Normal walking speed is 360 ft.


Secondary Outcome Measures :
  1. Modified Ashworth Scale (MAS) [ Time Frame: Baseline (Day 1) and at 4-weeks to measure change ]
    Clinical measure of degree of spasticity. Score varies from 0=normal tome to 4=part rigid in flexion and extension. Lower the score the better the outcome.

  2. Discharge disposition [ Time Frame: 4-weeks ]
    Looks at effectiveness of rehabilitation as to how many patients are discharged home. Higher percentage 65% and above the better outcome.

  3. The Beck Depression Inventory (BDI) [ Time Frame: Baseline (Day 1) and at 4-weeks to measure change ]
    It is a 21 item self-report rating inventory measuring characteristic attitudes and symptoms of depression. It ranges in value from 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows: 0-9 indicates person is not depressed, 10-18 indicates mild-moderate depression, 19-29 indicates moderate-severe depression and 30-63 indicates severe depression.


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. All patients with acute hemorrhagic or ischemic stroke documented clinically and by neuroimaging.
  2. Medically stable from a cardio-respiratory stand point so that they can participate in daily therapies.
  3. Depressed patients will be included in the study
  4. Patients able to stand alone
  5. Patients able to provide a written informed consent, from cognitively intact patients (admission Mini Mental Scale Examination [MMSE] greater than or equal to 21).

Exclusion Criteria:

  1. Aphasic patients unable to communicate
  2. Confused patients
  3. Patients medically unstable
  4. Patients unable to stand alone
  5. Refusal to provide written informed consent
Contacts and Locations

Locations
Layout table for location information
United States, Oklahoma
Oklahoma City VA Medical Center
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
University of Oklahoma
Investigators
Layout table for investigator information
Principal Investigator: Meheroz H Rabadi, MD, MRCPI Affiliate; Oklahoma VA Health Care System
Tracking Information
First Submitted Date  ICMJE May 2, 2019
First Posted Date  ICMJE June 10, 2019
Last Update Posted Date April 13, 2020
Actual Study Start Date  ICMJE March 1, 2020
Estimated Primary Completion Date September 1, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 6, 2019)
  • The Functional Independence Measure (FIM™) [ Time Frame: Baseline (Day 1) and at 4-weeks to measure change ]
    It measure the degree of disability as well as the progress patients make throughout their medical rehabilitation programs. FIM Scale score varies from minimum of 18 to maximum of 126. Higher score better the outcome.
  • The two minute walk test (2-MWT) [ Time Frame: Baseline (Day 1) and at 4-weeks to measure change ]
    It assess the walking distance over two minutes while moving at a comfortable speed. using any ambulation aids (such as cane, walkers, and rollators) used in everyday life. Normal walking speed is 360 ft.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 6, 2019)
  • Modified Ashworth Scale (MAS) [ Time Frame: Baseline (Day 1) and at 4-weeks to measure change ]
    Clinical measure of degree of spasticity. Score varies from 0=normal tome to 4=part rigid in flexion and extension. Lower the score the better the outcome.
  • Discharge disposition [ Time Frame: 4-weeks ]
    Looks at effectiveness of rehabilitation as to how many patients are discharged home. Higher percentage 65% and above the better outcome.
  • The Beck Depression Inventory (BDI) [ Time Frame: Baseline (Day 1) and at 4-weeks to measure change ]
    It is a 21 item self-report rating inventory measuring characteristic attitudes and symptoms of depression. It ranges in value from 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows: 0-9 indicates person is not depressed, 10-18 indicates mild-moderate depression, 19-29 indicates moderate-severe depression and 30-63 indicates severe depression.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke
Official Title  ICMJE Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke
Brief Summary The goal of this study is to determine the efficacy of electromechanical exoskeleton-assisted gait training on rehabilitation functional outcomes in patients with stroke undergoing therapy in an in-patient rehabilitation facility.
Detailed Description

Abstract

Objective: The goal of this study is to determine the efficacy of electromechanical exoskeleton-assisted gait training on rehabilitation functional outcomes in patients with stroke undergoing therapy in an in-patient rehabilitation facility.

Background:

Method: The investigators will study 50 patients with stroke consecutively admitted to a designated stroke rehabilitation unit in the Oklahoma City VA Medical Center. All patients will receive their daily 3-hours conventional therapy, plus an hour of either exoskeleton or over-ground gait training 3 times per week for 60 minutes. Patients were assigned to either the experimental (exoskeleton) or the control (over-ground) groups by computer-generated randomization. This is an open-label pragmatic trial, where neither the patients nor the clinicians could be masked to the intervention. Institution review board (IRB) approval will be obtained for the protocol. The demographic data to be collected includes: age, gender, race/ethnicity, stroke onset to admission, stroke types (ischemic/hemorrhagic), and stroke severity (on the National Institute of Health Stroke Severity [NIHSS] scale. Admission and discharge total Functional Independence Measure (FIM), spasticity and depression scores, ambulation velocity over 2-minutes (2-MWT) in feet/minute, and discharge disposition. The intervention is Indego® exoskeleton. The primary outcome measures were: changes in the FIM, depression and spasticity scores. The secondary outcome measure was discharge disposition. Continuous variables were analyzed using Students t-test, ordinal variables were analyzed using Mann-Whitney, and the nominal variables were analyzed using Chi-square analyses.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Open label pragmatic study
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Stroke
  • Weakness of Extremities as Sequela of Stroke
Intervention  ICMJE
  • Device: Indego Exoskeleton
    Powered generated orthosis
  • Other: Standard Rehabilitation
    Standard Rehabilitation
Study Arms  ICMJE
  • Experimental: Exo-group
    Standard rehabilitation plus use of Exoskeleton
    Interventions:
    • Device: Indego Exoskeleton
    • Other: Standard Rehabilitation
  • Placebo Comparator: Control-Group
    Standard rehabilitation
    Intervention: Other: Standard Rehabilitation
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: June 6, 2019)
50
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 1, 2025
Estimated Primary Completion Date September 1, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. All patients with acute hemorrhagic or ischemic stroke documented clinically and by neuroimaging.
  2. Medically stable from a cardio-respiratory stand point so that they can participate in daily therapies.
  3. Depressed patients will be included in the study
  4. Patients able to stand alone
  5. Patients able to provide a written informed consent, from cognitively intact patients (admission Mini Mental Scale Examination [MMSE] greater than or equal to 21).

Exclusion Criteria:

  1. Aphasic patients unable to communicate
  2. Confused patients
  3. Patients medically unstable
  4. Patients unable to stand alone
  5. Refusal to provide written informed consent
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03980457
Other Study ID Numbers  ICMJE 10742
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party University of Oklahoma
Study Sponsor  ICMJE University of Oklahoma
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Meheroz H Rabadi, MD, MRCPI Affiliate; Oklahoma VA Health Care System
PRS Account University of Oklahoma
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

治疗医院